Urgent

Psychosis & schizophrenia in adults (NICE NG178)

NICE NG178 · Psychiatry / Behavioural
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

NICE NG178 ('Psychosis and schizophrenia in adults: prevention and management') sets out a recovery-oriented, multidisciplinary pathway. First-episode psychosis is a psychiatric urgency: it is referred to a specialist Early Intervention in Psychosis service, which provides assessment and coordinated biopsychosocial care. Treatment combines a single oral antipsychotic, chosen jointly with the person after discussing the likely benefits and side-effect profile (metabolic, extrapyramidal, prolactin, sedation, cardiac), with psychological therapy — cognitive behavioural therapy for psychosis (CBTp) offered to everyone and family intervention offered to all families in contact with the person. Because antipsychotics and the illness carry a high burden of weight gain, diabetes and cardiovascular disease, structured physical-health monitoring (weight, waist, glucose/HbA1c, lipids, blood pressure, pulse, prolactin and ECG where indicated) is built into care from baseline. Treatment-resistant schizophrenia — an inadequate response to two antipsychotics each given for an adequate trial, at least one a non-clozapine second-generation agent — is an indication for clozapine, which should not be delayed. Throughout, the physical health, employment, housing and carers' needs are addressed, and relapse is prevented with maintenance treatment and, where adherence or preference indicates, a long-acting injectable.

Red flags

  • First-episode psychosis — a psychiatric urgency: urgent EIP referral and a full organic screen
  • Risk to self (suicide/self-neglect) or to others, command hallucinations, or threatening/violent behaviour
  • Features of an ORGANIC cause: fever, fluctuating consciousness/delirium, focal neurology, seizures, dyskinesia or autonomic instability (anti-NMDA-receptor encephalitis, CNS infection, delirium)
  • Neuroleptic malignant syndrome on antipsychotics: rigidity, hyperthermia, autonomic instability, raised creatine kinase — a medical emergency
  • Catatonia (stupor, mutism, posturing, waxy flexibility) — needs urgent assessment
  • Clozapine patient who is unwell: fever/sore throat (agranulocytosis), chest pain/tachycardia (myocarditis) or no bowel motions (ileus) — urgent review

Assessment

Differential diagnosis

  • Organic / secondary psychosis: delirium, substance intoxication or withdrawal (stimulants, cannabis, alcohol), prescribed drugs (corticosteroids, dopaminergics), autoimmune / anti-NMDA-receptor encephalitis, CNS infection, epilepsy / post-ictal states, thyroid disease, Cushing's, B12 deficiency, SLE, HIV
  • Primary psychiatric: schizophrenia, schizoaffective disorder, delusional disorder, brief psychotic disorder
  • Mood disorder with psychotic features: bipolar mania and psychotic (severe) depression
  • Neurodevelopmental / dementia-related psychosis; severe PTSD / dissociation

Investigations

  • Full mental-state examination, risk assessment (self, others, self-neglect), capacity assessment and collateral history
  • Bloods: FBC, U&E, LFT, TFT, fasting glucose / HbA1c, lipid profile, calcium, CRP, B12 / folate and prolactin; HIV / syphilis serology where indicated
  • Urine and serum toxicology; pregnancy test in women of child-bearing potential
  • Baseline metabolic / cardiac work-up BEFORE an antipsychotic: weight, waist circumference, pulse, blood pressure and a 12-lead ECG (QTc)
  • CT / MRI brain (and consider lumbar puncture) if first episode with atypical or organic features — fever, focal signs, seizures, rapid onset, dyskinesia or autonomic instability

Management

  • 1. Ensure safety of the person and others; de-escalate; assess risk and capacity. Use rapid tranquillisation only if essential, per the local / NICE acute-agitation protocol.
  • 2. Exclude an organic cause with a full physical assessment and screen — never assume 'psychiatric' at a first presentation.
  • 3. Refer a suspected FIRST episode urgently to the Early Intervention in Psychosis service (NICE: assessment within 2 weeks). Do not start an antipsychotic for a first presentation outside specialist / mental-health agreement.
  • 4. Offer the full package: a single oral antipsychotic PLUS cognitive behavioural therapy for psychosis (CBTp) AND family intervention — medication alone is not sufficient.
  • 5. Choose the antipsychotic jointly with the person after discussing benefits and side-effect profile; do the baseline physical-health checks first; start at a low dose, titrate, and give an adequate trial (4-6 weeks at an optimal dose) before judging it ineffective. Do not use regular combined antipsychotics (except briefly during changeover or for clozapine augmentation) and do not use a loading dose.
  • 6. Monitor response, adherence, side effects and physical health on the NICE schedule; actively manage cardiovascular risk, weight and glucose, and offer smoking cessation.
  • 7. Acute relapse: review adherence and psychosocial stressors, optimise treatment; offer a long-acting injectable (depot) where covert non-adherence is a risk or the person prefers it.
  • 8. Treatment-resistant schizophrenia (inadequate response to two antipsychotics, each an adequate trial of >= 6 weeks and at least one a non-clozapine second-generation drug): offer CLOZAPINE — do not delay it.

Drugs & doses

First-line: ONE oral antipsychotic chosen jointly — e.g. aripiprazole (metabolically favourable, less sedating), risperidone (dose-related EPS / raised prolactin), olanzapine (effective but sedating and metabolically heavy), or quetiapine. Start low, titrate to an effective dose, and give an adequate 4-6 week trial before switching.
Avoid routine combined antipsychotics (except changeover or clozapine augmentation) and avoid loading doses.
Rapid tranquillisation if acutely disturbed: IM lorazepam, or IM antipsychotic +/- promethazine, per the local protocol with physical monitoring [follow local RT policy / doses].
Treatment-resistant schizophrenia: CLOZAPINE under specialist care — titrate slowly; mandatory FBC / absolute neutrophil count monitoring for agranulocytosis, and watch for myocarditis, constipation / ileus, seizures, hypersalivation and sedation.
Maintenance / relapse prevention: continue the effective antipsychotic; offer a long-acting injectable (depot) where adherence is a concern or the person prefers it.
Manage physical health: treat metabolic and cardiovascular risk, offer smoking-cessation support, and review medication-induced weight gain, prolactin elevation and QTc.

Disposition

Urgent referral to Early Intervention in Psychosis / the crisis team for a first episode or relapse. Admit (informally, or under the Mental Health Act if the person lacks capacity or declines and is at significant risk) when there is risk to self or others, an inability to care for self, or diagnostic / organic uncertainty; use a medical bed if an organic cause is suspected. After the first year, physical-health monitoring is shared with the GP under agreed shared-care arrangements.

Complications & pitfalls

  • Suicide and self-harm (markedly raised risk, especially early illness)
  • Premature cardiovascular mortality and metabolic syndrome, weight gain and type-2 diabetes
  • Extrapyramidal side effects, akathisia and tardive dyskinesia; hyperprolactinaemia
  • Neuroleptic malignant syndrome; QTc prolongation / arrhythmia
  • Clozapine-specific: agranulocytosis, myocarditis / cardiomyopathy, ileus, seizures
  • Relapse, social / occupational decline, housing instability and comorbid substance misuse

Exam pearls

  • NICE: a suspected first episode of psychosis is an urgent EIP referral — and you should not start antipsychotics for a first presentation outside specialist agreement; refer first.
  • Everyone with psychosis should be offered CBT for psychosis AND family intervention, not medication alone.
  • Give each antipsychotic an adequate trial (4-6 weeks at an optimal dose) and use one drug at a time before deciding it has failed.
  • Treatment-resistant schizophrenia (failed two antipsychotics) is a clear indication for clozapine — delaying it is a common, harmful error.
  • Physical health kills in schizophrenia: monitor weight, glucose/HbA1c, lipids, BP and ECG from baseline, manage cardiovascular risk and offer smoking cessation.
  • At a first or acute presentation, screen hard for an organic cause (delirium, drugs, anti-NMDA-receptor encephalitis) before anchoring on a psychiatric diagnosis — see the Acute psychosis (medical screen) protocol.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.